Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
51 - 100 out of 159Page size: 50
  1. 2019
  2. Published

    Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Bang-Christensen, S. R., Pedersen, R. S., Pereira, M. A., Clausen, T. M., Løppke, C., Sand, N. T., Ahrens, T. D., Jørgensen, A. M., Lim, Y. C., Goksøyr, L., Choudhary, S., Gustavsson, T., Dagil, R., Daugaard, M., Sander, A. F., Torp, M. H., Søgaard, M., Theander, T. G., Østrup, O., Lassen, U. & 3 others, Hamerlik, P., Salanti, Ali & Agerbæk, Mette Ørskov, 2019, In: Cells. 8, 9, 21 p., 998.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Nørøxe, D. S., Østrup, O., Yde, C. W., Ahlborn, L. B., Nielsen, Finn Cilius, Michaelsen, Signe Regner, Larsen, V. A., Skjøth-Rasmussen, J., Brennum, J., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 2019, In: OncoTarget. 10, 43, p. 4397-4406 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Combining PARP inhibition with PD-1 inhibitors

    Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 9, p. 1196-1198 3 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  5. Published

    Copenhagen prospective personalized oncology (COPPO)—Clinical utility of using molecular profiling to select patients to phase I trials

    Tuxen, I. V., Rohrberg, K. S., Oestrup, O., Ahlborn, L. B., Schmidt, A. Y., Spanggaard, I., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Yde, C. W., Mau-Sørensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2019, In: Clinical Cancer Research. 25, 4, p. 1239-1247 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, 2019, In: Trials. 20, 12 p., 708.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Extracranial metastases in glioblastoma—Two case stories

    Schou Nørøxe, D., Michaelsen, Signe Regner, Broholm, H., Møller, Søren, Skovgaard Poulsen, H. & Lassen, Ulrik Niels, 2019, In: Clinical Case Reports. 7, 2, p. 289-294 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

    Bertelsen, B., Tuxen, I. V., Yde, C. W., Gabrielaite, M., Torp, M. H., Kinalis, S., Oestrup, O., Rohrberg, K., Spangaard, I., Santoni Rugiu, Eric, Wadt, Karin Anna Wallentin, Mau-Sorensen, M., Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2019, In: npj Genomic Medicine. 4, 1, 11 p., 13.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    How I treat NTRK gene fusion-positive cancers

    Lassen, Ulrik Niels, 2019, In: ESMO Open. 4, Suppl. 2, 3 p., e000612.

    Research output: Contribution to journal › Review › Research › peer-review

  10. Published

    Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P-Y., Dutoit, V., Wick, W., Platten, M. & 17 others, Winkler, F., von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, Ulrik Niels, Ottensmeier, C., van der Burg, S. H., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H., Sahin, U., Singh, H. & Admon, A., 2019, In: Molecular and Cellular Proteomics. 18, 6, p. 1255-1268 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Viller Tuxen, I., Barlebo Ahlborn, L., Mau-Soerensen, M., Staal Rohrberg, K., Nielsen, Finn Cilius, Oestrup, O., Westmose Yde, C., Richter Vogelius, I. & Lassen, Ulrik Niels, 2019, In: British Journal of Cancer. 121, 2, p. 125-130 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  12. Published

    Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

    de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J. P., Arkenau, H. T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., Rangwala, R. A. & 1 others, Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 3, p. 383-393 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  13. 2018
  14. Published

    Patient information in phase 1 trials: A systematic review

    Gad, K. T., Lassen, Ulrik Niels, Mau-Søerensen, M., Høybye, M. T. & Johansen, Christoffer, Mar 2018, In: Psycho-Oncology. 27, 3, p. 768-780

    Research output: Contribution to journal › Review › Research › peer-review

  15. Published

    A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

    de Weger, V. A., Goel, S., von Moos, R., Schellens, J. H. M., Mach, N., Tan, E., Anand, S., Scott, J. W. & Lassen, Ulrik Niels, 2018, In: Cancer Chemotherapy and Pharmacology. 81, 1, p. 73-80 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  16. Published

    A systematic review of targeted agents for non-small cell lung cancer

    Vestergaard, H. H., Christensen, M. R. & Lassen, Ulrik Niels, 2018, In: Acta Oncologica. 57, 2, p. 176-186 11 p.

    Research output: Contribution to journal › Review › Research › peer-review

  17. Published

    Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

    Toft, A., Urup, T., Christensen, I. J., Michaelsen, Signe Regner, Lukram, B., Grunnet, K., Kosteljanetz, M., Larsen, V. A., Lassen, Ulrik Niels, Broholm, H. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 2, p. 165-174 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  18. Published

    Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Ahlborn, L. B., Tuxen, I. V., Mouliere, F., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W., Oestrup, O. & Mau-Sorensen, M., 2018, In: OncoTarget. 9, 66, p. 32570-32579

    Research output: Contribution to journal › Journal article › Research › peer-review

  19. Published

    Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

    Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V. & 18 others, Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. P. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S. & Hyman, D. M., 2018, In: The New England Journal of Medicine. 378, 8, p. 731-739

    Research output: Contribution to journal › Journal article › Research › peer-review

  20. Published

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    Massard, C., Azaro, A., Soria, J., Lassen, Ulrik Niels, Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, 9, p. 1911-1917 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  21. Published

    Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

    Michaelsen, Signe Regner, Urup, T., Olsen, L. R., Broholm, H., Lassen, Ulrik Niels & Poulsen, H. S., 2018, In: Journal of Neuro-Oncology. 137, 3, p. 533-542 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  22. Published

    Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors

    Spanggaard, I., Oestrup, O., Bertelsen, B., Rohrberg, K. S., de Schmidt, A. Y., Tuxen, I. V., Ahlborn, L. B., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Marvig, R. L., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Yde, C. W. & Mau-Sørensen, M., 2018, In: European Journal of Cancer. 103, Suppl. 1, p. E142-E143 2 p.

    Research output: Contribution to journal › Conference abstract in journal › Research

  23. Published

    Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Johansen, M. D., Urup, T., Holst, C. B., Christensen, I. J., Grunnet, K., Lassen, Ulrik Niels, Friis, S. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 9-10, p. 512-519 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  24. Published

    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Schneeweiss, A., Park-Simon, T. W., Albanell, J., Lassen, U., Cortés, J., Dieras, V., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., Martinez-Garcia, M., Gonzalez, I., Lopez-Martin, J., Welt, A., Levy, C., Joly, F., Michielin, F., Jacob, W., Adessi, C., Moisan, A. & 7 others, Meneses-Lorente, G., Racek, T., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2018, In: Investigational New Drugs. 36, 5, p. 848-859 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  25. Published

    TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

    Kummar, S. & Lassen, Ulrik Niels, 2018, In: Targeted Oncology. 13, 5, p. 545-556

    Research output: Contribution to journal › Review › Research › peer-review

  26. Published

    VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

    Michaelsen, Signe Regner, Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T., Villingshøj, M., Lukacova, S., Skjøth-Rasmussen, J., Brennum, J., Kjær, Andreas, Lassen, Ulrik Niels, Stockhausen, M., Poulsen, H. S. & Hamerlik, P., 2018, In: Neuro-Oncology. 20, 11, p. 1462-1474

    Research output: Contribution to journal › Journal article › Research › peer-review

  27. 2017
  28. Published

    Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jul 2017, In: B M J Open. 7, 7, 10 p., e015579.

    Research output: Contribution to journal › Journal article › Research › peer-review

  29. Published

    Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jun 2017, In: Pharmacology Research & Perspectives. 5, 3, 9 p., e00317.

    Research output: Contribution to journal › Journal article › Research › peer-review

  30. Published

    Detection of copy number alterations in cell-free tumor DNA from plasma

    Østrup, O., Ahlborn, L. B., Lassen, Ulrik Niels, Mau-Sørensen, M. & Nielsen, Finn Cilius, Jun 2017, In: BBA Clinical. 7, p. 120-126 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  31. Published

    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

    Urup, T., Staunstrup, L. M., Michaelsen, Signe Regner, Vitting-Seerup, K., Bennedbæk, M., Toft, A., Olsen, L. R., Jønson, L., Issazadeh-Navikas, Shohreh, Broholm, H., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 18 Apr 2017, In: BMC Cancer. 17, 10 p., 278.

    Research output: Contribution to journal › Journal article › Research › peer-review

  32. Published

    Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols

    Ahlborn, L. B., Madsen, M., Jonson, L., Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W. & Mau-Sorensen, M., 2017, In: Clinical Laboratory. 63, 10, p. 1755-1759

    Research output: Contribution to journal › Journal article › Research › peer-review

  33. Published

    Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

    Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., Giménez-Capitán, A., Drozdowskyj, A., Viteri, S., Larsen, M. R., Lassen, Ulrik Niels, Felip, E., Bivona, T. G., Ditzel, H. J. & Rosell, R., 2017, In: Nature Communications. 8, 14 p., 410.

    Research output: Contribution to journal › Journal article › Research › peer-review

  34. Published

    Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

    Meulendijks, D., Jacob, W., Voest, E. E., Mau-Sorensen, M., Martinez-Garcia, M., Taus, A., Fleitas, T., Cervantes, A., Lolkema, M. P., Langenberg, M. H. G., De Jonge, M. J., Sleijfer, S., Han, J-Y., Calles, A., Felip, E., Kim, S-W., Schellens, J. H. M., Wilson, S., Thomas, M., Ceppi, M. & 11 others, Meneses-Lorente, G., James, I., Vega-Harring, S., Dua, R., Nguyen, M., Steiner, L., Adessi, C., Michielin, F., Bossenmaier, B., Weisser, M. & Lassen, Ulrik Niels, 2017, In: Clinical Cancer Research. 23, 18, p. 5406-5415

    Research output: Contribution to journal › Journal article › Research › peer-review

  35. 2016
  36. Published

    First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

    Abdul Razak, A. R., Mau-Sørensen, M., Gabrail, N. Y., Gerecitano, J. F., Shields, A. F., Unger, T. J., Saint-Martin, J. R., Carlson, R., Landesman, Y., McCauley, D., Rashal, T., Lassen, Ulrik Niels, Kim, R., Stayner, L., Mirza, M. R., Kauffman, M., Shacham, S. & Mahipal, A., Dec 2016, In: Journal of Clinical Oncology. 34, 34, p. 4142-4150 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  37. Published

    Hallmarks of glioblastoma: a systematic review

    Nørøxe, D. S., Poulsen, H. S. & Lassen, Ulrik Niels, Dec 2016, In: E S M O Open. 1, 6, 9 p., e000144.

    Research output: Contribution to journal › Review › Research › peer-review

  38. Published

    Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

    Urup, T., Michaelsen, Signe Regner, Olsen, L. R., Toft, A., Christensen, I. J., Grunnet, K., Winther, Ole, Broholm, H., Kosteljanetz, M., Issazadeh-Navikas, Shohreh, Poulsen, H. S. & Lassen, Ulrik Niels, Oct 2016, In: Molecular Oncology. 10, 8, p. 1160-1168

    Research output: Contribution to journal › Journal article › Research › peer-review

  39. Published

    Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

    Plesner, T., Arkenau, H-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U. N., Laubach, J. P., Palumbo, A., Lisby, S., Basse, L., Wang, J., Sasser, A. K., Guckert, M. E., de Boer, C., Khokhar, N. Z., Yeh, H., Clemens, P. L., Ahmadi, T., Lokhorst, H. M. & 1 others, Richardson, P. G., Oct 2016, In: Blood. 128, 14, p. 1821-1828

    Research output: Contribution to journal › Journal article › Research › peer-review

  40. Published

    First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

    Dienstmann, R., Lassen, Ulrik Niels, Cebon, J., Desai, J., Brown, M. P., Evers, S., Su, F., Zhang, W., Boisserie, F., Lestini, B., Schostack, K., Meresse, V. & Tabernero, J., Apr 2016, In: Targeted Oncology. 11, 2, p. 149-56 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  41. Published

    Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma

    Nedergaard, M. K., Michaelsen, Signe Regner, Perryman, L., Erler, Janine, Poulsen, H. S., Stockhausen, M., Lassen, Ulrik Niels & Kjær, Andreas, Mar 2016, In: Nuclear Medicine and Biology. 43, 3, p. 198-205 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  42. Published

    Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

    Meulendijks, D., Lassen, Ulrik Niels, Siu, L. L., Huitema, A. D. R., Karanikas, V., Mau-Sørensen, M., Jonker, D. J., Hansen, A. R., Simcox, M. E., Schostack, K. J., Bottino, D., Zhong, H., Roessler, M., Vega-Harring, S. M., Jarutat, T., Geho, D., Wang, K., DeMario, M., Goss, G. D. & Schellens, J. H. M., 15 Feb 2016, In: Clinical Cancer Research. 22, 4, p. 858-67 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  43. Published

    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

    Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., Sleijfer, S., Mau-Sørensen, M., Thomas, M., Ceppi, M., Meneses-Lorente, G., James, I., Adessi, C., Michielin, F., Abiraj, K., Bossenmaier, B. & 3 others, Schellens, J. H. M., Weisser, M. & Lassen, Ulrik Niels, 15 Feb 2016, In: Clinical Cancer Research. 22, 4, p. 877-85 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  44. Published

    Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma

    Persson, M., Nedergaard, M. K., Brandt-Larsen, M., Skovgaard, D., Jørgensen, Jesper Tranekjær, Michaelsen, Signe Regner, Madsen, J., Lassen, Ulrik Niels, Poulsen, H. S. & Kjær, Andreas, Feb 2016, In: Journal of Nuclear Medicine. 57, 2, p. 272-278 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  45. Published

    Actionable targets in recurrent bile duct and pancreatic cancer in a prospective cohort of patients evaluated by whole exome sequencing and SNP array analysis

    Tuxen, I. E. V., Mau-Sørensen, M., Yde, C. W., Jønson, L., Oestrup, O., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Journal of Clinical Oncology. 34, 15, Suppl., 1 p., e23256.

    Research output: Contribution to journal › Conference abstract in journal › Research

  46. Published

    Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials

    Tuxen, I. V., Yde, C. W., Mau-Sorensen, M., Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Annals of Oncology.

    Research output: Contribution to journal › Journal article › Research › peer-review

  47. Published

    Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

    Urup, T., Dahlrot, R. H., Grunnet, K., Christensen, I. J., Michaelsen, Signe Regner, Toft, A., Larsen, V. A., Broholm, H., Kosteljanetz, M., Hansen, S., Poulsen, H. S. & Lassen, Ulrik Niels, 2016, In: Acta Oncologica. 55, 4, p. 418-22 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  48. Published

    Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors

    Mau-Sørensen, M., Ahlborn, L. B., Jønson, L., Oestrup, O., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels & Yde, C. W., 2016, In: Journal of Clinical Oncology. 34, 15 (Suppl. S), 11531.

    Research output: Contribution to journal › Conference abstract in journal › Research

  49. Published

    Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2: a retrospective case series

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, Kåre, Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sørensen, M. & Hofland, K. F., 2016, In: International Journal of Neuroscience. 126, 11, p. 1002-6 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  50. 2015
  51. Published

    The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, K., Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sorensen, M. & Hofland, K. F., Dec 2015, In: European Archives of Oto-Rhino-Laryngology. 272, 12, p. 3627-3633 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  52. Published

    Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

    Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N. & 1 others, Richardson, P. G., 24 Sep 2015, In: New England Journal of Medicine. 373, 13, p. 1207-19 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  53. Published

    Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

    Grunnet, M., Christensen, I. J., Lassen, Ulrik Niels, Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitlal, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sørensen, M., Jul 2015, In: European journal of cancer (Oxford, England : 1990). 51, 11, p. 1381-8 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  54. Published

    Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

    Lassen, Ulrik Niels, Chinot, O. L., McBain, C., Mau-Sørensen, M., Larsen, V. A., Barrie, M., Roth, P., Krieter, O., Wang, K., Habben, K., Tessier, J., Lahr, A. & Weller, M., Jul 2015, In: Neuro-Oncology. 17, 7, p. 1007-15 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  55. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

    Mau-Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, Ulrik Niels, Büchler, W., Martinius, H. & Tabernero, J., May 2015, In: Cancer Chemotherapy and Pharmacology. 75, 5, p. 1065-73 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 Next

ID: 4952653